Biotech News
FierceBiotech is a respected source for coverage of the biotech industry. Find news on biotech companies like GlaxoSmithKline, Pfizer and Merck as well as the latest on FDA approvals, venture capital, mergers & acquisitions and more. For more information and analysis on these topics, please visit our biotechnology reports.
FDA commish counters industry critics on expert conflict rules
There's been an ongoing debate in biopharma circles over the impact a shortage of drug experts is having on the FDA's panel review process. But anyone looking for the agency to welcome changes in the Read more...
Scoring winners and losers in Japan pharma M&A bout
Japan's biggest pharma players have been roaming the world in recent years in a restless search for new acquisitions. They've been looking for deals to put an extra oomph into their earnings. Now The Read more...
Idenix gets good news on hep C trial, but can't compete with Gilead
Idenix put out the news this morning that the FDA had lifted a partial hold on its hepatitis C drug IDX184--and then watched its share price slide. In a sign of just how volatile the whole hepatitis Read more...
AstraZeneca's R&D chief in China lays out $100M strategy
One of the hottest trends in the global R&D business in recent years has been Big Pharma's huge investment in China. Among all the emerging countries, China's massive, fast-growing economy has Read more...
Gilead shares surge as hep C drug scores a cure for big patient population
Gilead Sciences ($GILD) received its first bonus from the monster $10.8 billion deal to acquire Pharmasset ($VRUS) after CSO Norbert Bischofberger told analysts yesterday evening that PSI-7977 Read more...
Threshold, Merck KGaA strike $525M licensing deal for promising cancer drug
The dealmakers at South San Francisco-based Threshold Pharmaceuticals ($THLD) have crafted a $525 million licensing pact with Merck KGaA covering its late-stage cancer drug TH-302. Threshold snagged Read more...
U.S. funding drop threatens San Diego life sciences industry
The life sciences job juggernaut in metro San Diego expanded through the ongoing economic downturn and will produce another 6,000 jobs through 2014, according to a new report. But a big drop in Read more...
Is Lilly betting the farm on its high-stakes Alzheimer's gamble?
Now that the patent cliff has arrived right on time for Eli Lilly ($LLY), the big question this year is whether or not its massive gamble on the Alzheimer's drug solanezumab will pay off. That's Read more...
AB soars on promising survival data from Phase II tumor study
Shares of Paris-based AB Science shot up yesterday after the drug developer reported strong efficacy results from a midstage study of its experimental drug for gastrointestinal tumors. The treatment, Read more...
Czechs beef up investment in biotech research
The Czech Republic is substantially boosting its investment in biotechnology research, with plans to build a massive research center near Prague set to employ 600 people, the Prague Daily Monitor is Read more...
Pharma defeats biotech push for rapid approval program
Biotechs butted heads with their far-larger pharmaceutical allies over a key lobbying issue, and lost. As Bloomberg reports, biotechnology companies threw their weight behind a plan drafted by North Read more...
UPDATED: AstraZeneca cutting 2,200 R&D jobs, slashing neuroscience in restructuring
Hit with sliding profits, a weak late-stage pipeline and a troubling track record on clinical trials, AstraZeneca ($AZN) has decided to trigger another round of layoffs, with 2,200 R&D staffers Read more...
Merrimack Pharma scraps IPO
Merrimack Pharmaceuticals' attempt to buck the trend on IPOs ended in failure today. The developer, a 2011 Fierce 15 company, has 5 drugs in the clinic and reportedly scrapped its offering saying Read more...
Investigators tout promising breast cancer vax data from small study
Investigators at the University of Pennsylvania say an experimental breast cancer vaccine designed to spur a patient's dendritic cells to attack cancer cells has proved promising in a small human Read more...
Sangamo spikes on $13M discovery pact with Shire
Shares of Sangamo BioSciences spiked 22% this morning after the Richmond, CA-based biotech announced plans to team up with Shire on a discovery pact to find new treatments for hemophilia and other Read more...
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
